Histone deacetylase inhibitors as anticancer drugs

T Eckschlager, J Plch, M Stiborova… - International journal of …, 2017 - mdpi.com
Carcinogenesis cannot be explained only by genetic alterations, but also involves
epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic …

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

KJ Falkenberg, RW Johnstone - Nature reviews Drug discovery, 2014 - nature.com
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are
often caused by genetic defects that result in functional deregulation of epigenetic proteins …

New and emerging HDAC inhibitors for cancer treatment

AC West, RW Johnstone - The Journal of clinical …, 2014 - Am Soc Clin Investig
Epigenetic enzymes are often dysregulated in human tumors through mutation, altered
expression, or inappropriate recruitment to certain loci. The identification of these enzymes …

The role of enhancers in cancer

I Sur, J Taipale - Nature Reviews Cancer, 2016 - nature.com
Enhancer elements function as the logic gates of the genetic regulatory circuitry. One of their
most important functions is the integration of extracellular signals with intracellular cell fate …

Anticancer activities of histone deacetylase inhibitors

JE Bolden, MJ Peart, RW Johnstone - Nature reviews Drug discovery, 2006 - nature.com
Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and
have a key role in the epigenetic regulation of gene expression. In addition, the activity of …

Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy

AK Singh, A Bishayee, AK Pandey - Nutrients, 2018 - mdpi.com
Cancer initiation and progression are the result of genetic and/or epigenetic alterations.
Acetylation-mediated histone/non-histone protein modification plays an important role in the …

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

S Minucci, PG Pelicci - Nature Reviews Cancer, 2006 - nature.com
Histone deacetylases (HDACs) are considered to be among the most promising targets in
drug development for cancer therapy, and first-generation histone deacetylase inhibitors …

Histone deacetylase inhibitors: molecular mechanisms of action

WS Xu, RB Parmigiani, PA Marks - Oncogene, 2007 - nature.com
This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors
(HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …

G9a dictates neuronal vulnerability to inflammatory stress via transcriptional control of ferroptosis

N Rothammer, MS Woo, S Bauer, L Binkle-Ladisch… - Science …, 2022 - science.org
Neuroinflammation leads to neuronal stress responses that contribute to neuronal
dysfunction and loss. However, treatments that stabilize neurons and prevent their …

Histone deacetylase inhibitors in cancer therapy

AA Lane, BA Chabner - Journal of clinical oncology, 2009 - ascopubs.org
Purpose Epigenetic processes are implicated in cancer causation and progression. The
acetylation status of histones regulates access of transcription factors to DNA and influences …